[by 실시간 바카라사이트, Suin] Vaxcellbio announced on April 22 the final registration of its original patent in Korea, covering its proprietary natural killer (NK) cell manufacturing technology and therapeutic application for the treatment of liver cancer.The patent encompasses a manufacturing method capable of mas
[by Kang, In Hyo] PeopleBio announced on April 22 the publication of research findings demonstrating that postoperative delirium can be predicted by measuring ‘blood beta-amyloid aggregation’ using the ‘AlzOn’ blood test. The study was featured in the latest issue of the international academic journ
[by 실시간 바카라사이트, Yong Jun] Vaxcellbio revealed on April 23 that it has officially registered a Japanese patent for its core immune cell therapy technology named ‘Composition for proliferation of natural killer cells containing feeder cells.’The patented technology represents an advanced platform developed by
[by 실시간 바카라사이트, Yong Jun] Gencurix announced that its breast cancer prognostic test, GenesWell BCT, has demonstrated enhanced prognostic stratification compared to Oncotype DX, the globally recognized 21-gene expression assay. The study underscores GenesWell BCT’s ability to more effectively identify high-r
[by 실시간 바카라사이트, Yong Jun] Abion announced on April 22 that it will present supplementary data at the upcoming American Association for Cancer Research (AACR) Annual Meeting, including data on drug-drug interactions (DDI) observed with the co-administration of ‘vabametkib (development code: ABN401),’ a hepat
[by 실시간 바카라사이트, Suin] SillaJen announced on April 22 that it has acquired all patents and rights to the anticancer drug candidate 'BAL0891' from the Dutch biotechnology company Crossfire through a transaction valued at CHF 2 million Swiss francs (approximately USD 2.4 million).Crossfire was the original dev
[by 실시간 바카라사이트, Yong Jun] Huons Meditech, a medical device company of the Huons Group, has begun exporting an electrically powered drug delivery system and the dedicated microneedle designed for gynecological use to Taiwan, actively expanding into the global market.On April 22, Huons Meditech announced that
[by 실시간 바카라사이트, Yong Jun] ToolGen, a gene editing company, announced on April 21 that it has filed a patent infringement lawsuit in the British court against Vertex Pharmaceuticals and its commercial partners, Lonza and RoslinCT, concerning the gene editing treatment CASGEVY.ToolGen secured a patent for its
[by Kang, In Hyo] “The past four years have been an incredible journey. We pushed forward with a clear vision, and within just three years of launching the company, we were able to demonstrate our technological strength by successfully exporting our main pipeline in the preclinical stage, NXI-101 (d
[by Kang, In Hyo] Hugel, a leading global medical aesthetics company, said on April 21 that has recently hosted a launch seminar for its botulinum toxin Botulax and hyaluronic acid dermal filler Revolax at Holiday Inn Almaty, Kazakhstan, for local dermatologists and plastic surgeons.Kazakhstan, the
[by Sung, Jae Jun] Orum Therapeutics (“Orum” or the “Company”), a clinical-stage biotechnology company pioneering the field of degrader-antibody conjugates (DACs), announced on April 21 the appointment of Sang Hyun (Shawn) Lee, Ph.D., as Vice President, Research Site Head, Korea. Dr. Lee brings over
[더바이오 강인효 기자] “숨 가쁘게 달려온 4년이었습니다. 뚜렷한 목표를 가지고 기민하게 움직였고, 그 결과 회사 설립 3년 만에 전임상 단계의 주력 파이프라인인 ‘NXI-101(개발코드명)’을 글로벌 기술수출하면서 회사의 기술 경쟁력을 입증하는데 성공했습니다.”올해 창립 4주년을 맞은 넥스아이의 윤경완 대표는 지난 17일 서울 송파구 문정동 소재 본사에서 와 인터뷰를 갖고 이같이 말했다. 넥스아이는 창립 4주년을 계기로 또 다른 목표를 향해 새로운 페이지를 써 내려가고 있다.내년에는 후속 파이프라인인 ‘NXI-201(
[by 실시간 바카라사이트, Suin] Huons Meditech, a medical device company of the Huons Group, is strengthening its competitiveness in the urology devices market by introducing an extracorporeal shock wave therapy (ESWT) device, ‘IMPO88 Plus,’ for erectile dysfunction (ED).On April 18, Huons Meditech (CEO Lee Jin-suk)
[by 실시간 바카라사이트, Suin] Huons Group participated in a dermatology exhibition in Dubai, Middle East, unveiling the group’s innovative products and cutting-edge technologies to enhance global competitiveness.On April 17, Humedix, Huons Meditech, and Huons BioPharma announced that the group companies had partici
[by 실시간 바카라사이트, Yong Jun] HLB Pep (formerly Anygen), a company specializing in the development and production of peptide-based materials, announced on April 16 that it participated in the recent pharmaceutical exhibition ‘CPHI Japan 2025.’ During the event, the company engaged in numerous discussions with a
[by 실시간 바카라사이트, Suin] L&C Bio, a company specializing in regenerative medicine for human tissue, announced on April 16 that it has secured a patent for its proprietary technology of ‘ultra-fine acellular dermis manufacturing method,’ a technology designed to be injected into damaged soft tissue regions.The
[by 실시간 바카라사이트, Yong Jun] CMG Pharmaceutical, a subsidiary of CHA Biotech, announced on April 16 that it had received product approval from the U.S. Food and Drug Administration (FDA) for ‘Mezofy,’ a treatment for schizophrenia. Mezofy is an ‘oral Film’ formulation containing aripiprazole, developed by CMG
[by 실시간 바카라사이트, Suin] MetaVia, a subsidiary of Dong-A ST, announced on April 16 that topline results from Part 2 of its global Phase 1 clinical trial demonstrated the excellent weight loss efficacy, safety, and tolerability of ‘DA-1726 (development code)’, a glucagon-like peptide 1 (GLP-1)/glucagon dual ago
[by 실시간 바카라사이트, Suin] EuBiologics announced on April 15 that it entered into a supply agreement with UNICEF Mozambique to supply its oral cholera vaccine, 'Euvichol,' with a total contract value of KRW 8.35798 billion (approximately USD 5.8 million).The contract amount represents 8.70% of EuBiologics’ recen
[by 실시간 바카라사이트, Suin] GENCURIX announced on April 15 that its breast cancer prognostic test, GenesWell BCT (Breast Cancer Test), has demonstrated superior accuracy in predicting recurrence risk compared to leading international genetic assays. The results, recently accepted for publication in the renowned p
